Nurix Therapeutics
San Francisco, US · Founded 2009 · 5 known investors
Nurix Therapeutics develops targeted protein degradation medicines, including degrader-antibody conjugates (DACs), designed to eliminate disease-causing proteins using the cell's natural degradation machinery. It uses a DEL-AI drug discovery engine to advance a multi-modal clinical pipeline targeting diseases in oncology, immunology, and neurology.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
AT
Arthur T. SandsExecutive
TK
Timothy KutzkeyNamed on SEC filing
Board
DG
David GoeddelBoard director
MG
Mark GoldsmithBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$139.4M disclosed across 3 rounds · 2013–2020
▶$120.2MraisedMar 2020 · 23 investors · OtherRule 506(b)
▶$120.2MraisedMar 2020 · 23 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Arthur SandsExecutive Officer, Director
- Lori KunkelDirector
- Julia GregoryDirector
- Jeff TongDirector
- Robert TjianDirector
- David LaceyDirector
- Christine RingExecutive Officer
- Hans van HouteExecutive Officer
- Leon ChenDirector
- Offering amount
- $120.2M
- Amount sold
- $120.2M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17MraisedSep 2015 · 1 investors · OtherRule 506(b)
▶$17MraisedSep 2015 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- David GoeddelDirector
- Mark GoldsmithDirector
- Arthur T. SandsExecutive Officer, Director
- Timothy KutzkeyExecutive Officer, Director
- Offering amount
- $17M
- Amount sold
- $17M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedJan 2014 · 2 investors · OtherRule 506(b)
▶$2.1MraisedJan 2014 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Mark GoldsmithExecutive Officer, Director
- Timothy KutzkeyExecutive Officer, Director
- David GoeddelDirector
- Offering amount
- $25.1M
- Amount sold
- $2.1M
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right? - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Nurix Therapeutics do?
- Nurix Therapeutics develops targeted protein degradation medicines, including degrader-antibody conjugates (DACs), designed to eliminate disease-causing proteins using the cell's natural degradation machinery. It uses a DEL-AI drug discovery engine to advance a multi-modal clinical pipeline targeting diseases in oncology, immunology, and neurology.
- Who are Nurix Therapeutics's investors?
- Nurix Therapeutics's investors include Bain Capital Life Sciences, EcoR1 Capital, Foresite Capital, Sofinnova Ventures, The Column Group.
- How much funding has Nurix Therapeutics raised?
- Nurix Therapeutics has disclosed $139.4M raised across 3 rounds.
- Where is Nurix Therapeutics headquartered?
- Nurix Therapeutics is headquartered in San Francisco, US.